NCT05105048已完成1 期
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 When Administered to Healthy Japanese Adults (18-40 Years of Age) in the United States
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 6
- 主要终点
- Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
研究概览
简要总结
The main objective of this study is to evaluate the safety, reactogenicity, and immunogenicity of the mRNA-1647 vaccine administered according to a 3-study injection schedule in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive Japanese adults 18 to 40 years of age in the United States.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participant is a Japanese Adult 18-40 years of age at the time of consent who, in the opinion of the investigator, is in good health based on review of medical history and screening physical examination. Japanese participants are defined as individuals born in Japan, with both parents and 4 grandparents who were born in Japan, and who have not lived outside of Japan for more than 10 years in total.
- •For the CMV-seronegative groups: Participant is serum CMV IgG negative/ IgM negative.
- •For the CMV-seropositive groups: Participant is either serum CMV IgG positive/IgM negative or IgG positive/IgM positive.
- •Participant has a body mass index (BMI) from ≥18 kilograms (kg)/square meter (m^2) to ≤35 kg/m^2, inclusive.
排除标准
- •History of a diagnosis or condition that, in the judgment of the investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures. Clinically unstable is defined as a diagnosis or condition requiring significant changes in management or medication within the 2 months prior to screening and includes ongoing workup of an undiagnosed illness that could lead to a new diagnosis or condition.
- •Participant has elevated liver function tests, defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP), or elevated creatinine or reduced platelets, with a toxicity score of Grade ≥1 at screening.
- •Participant has laboratory test results (hematology, chemistry, and coagulation) with a toxicity score of Grade ≥1 at screening.
- •Received or plans to receive any non-study vaccine <28 days prior to any study injection; in addition, the following criteria for COVID-19 and influenza vaccines apply:
- •i. Any COVID-19 vaccination series must have been completed a minimum of 28 days prior to receiving any dose of the study injection.
- •ii. COVID-19 vaccines (regardless of manufacturer) must be administered at least 28 days prior to or after any study injection.
- •iii. Influenza vaccines may be administered >14 days prior to or after any study injection.
- •Participant has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months before the day of first injection (Day 1) (for corticosteroids, >5 mg/day of prednisone equivalent) or plans to do so during the course of the study. Inhaled, nasal, and topical steroids are allowed.
- •Participant has received an antiviral with activity against CMV (ganciclovir, valganciclovir, foscarnet, cidofovir, letermovir, acyclovir, valacyclovir) within 2 weeks before the first injection or plans to do so during the course of the study.
- •Participant received any investigational CMV vaccine.
- •History of myocarditis, pericarditis, or myopericarditis.
- •Reported medical history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV); or a positive screening test for hepatitis B surface antigen (HbSAg), hepatitis C antibodies, or HIV 1 or 2 antibodies.
- •Other inclusion and exclusion criteria may apply.
结局指标
主要结局
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
时间窗: Up to Day 176 (7 days after each injection)
Number of Participants With Unsolicited Adverse Events (AEs)
时间窗: Up to Day 197 (28 days after each injection)
Number of Participants With Medically-Attended AEs (MAAEs)
时间窗: Day 1 through 6 months after the last injection (up to Day 347)
Number of Participants With Serious AEs (SAEs)
时间窗: Day 1 through End of Study (EOS) (up to Day 347)
Number of Participants With AEs of Special Interest (AESIs)
时间窗: Day 1 through EOS (up to Day 347)
次要结局
- Geometric Mean Fold-Rise (GMFR) of nAb Against Epithelial Cell Infection and Against Fibroblast Infection(Days 29, 85, 169, 197, and 347)
- Proportion of Participants with ≥2-Fold, 3-Fold, and 4-Fold Increases in nAb over Baseline Against Epithelial Cell Infection and Against Fibroblast Infection(Days 29, 85, 169, 197, and 347)
- GMT of Anti-Glycoprotein B (gB) Specific Immunoglobulin G (IgG) and Anti-Pentamer Specific IgG as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)(Days 1, 29, 85, 169, 197, and 347)
- Proportion of Participants with ≥2-Fold, 3-Fold, and 4-Fold Increases Over Baseline in Anti-gB and Anti-Pentamer Specific IgG(Days 29, 85, 169, 197, and 347)
- Geometric Mean Titer (GMT) of Serum Neutralizing Anti-CMV Antibodies (nAbs) Against Epithelial Cell Infection and Against Fibroblast Infection(Days 1, 29, 85, 169, 197, and 347)
- GMFR of Anti-gB and Anti-Pentamer Specific IgG(Days 29, 85, 169, 197, and 347)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersRespiratory Syncytial VirusNCT06143046ModernaTX, Inc.360
已完成
1 期
A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female SubjectsPapillomavirus InfectionsNCT039291722A Pharma AB20
终止
1 期
A Phase 1, First in Human Study to Investigate the Safety and Tolerability of PA401Healthy VolunteersNCT01627002ProtAffin Biotechnologie AG49
已完成
1 期
A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy ParticipantsHealthyNCT02758392Janssen Research & Development, LLC54
已完成
1 期
Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19Covid19NCT04527575Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"100